Login to Your Account

Puma pounce: NDA filing arrives with extended disease-free survival data

By Michael Fitzhugh
Staff Writer

Friday, July 22, 2016

Shares of Puma Biotechnology Inc. (NYSE:PBYI) rose 20.3 percent Friday on word that the company has submitted an FDA NDA for its lead candidate, neratinib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription